南京医药股份有限公司2025年度第七期超短期融资券发行结果公告

Group 1 - The company has received approval to issue a total of up to RMB 60 billion in short-term financing bonds, with a registration validity of two years from October 29, 2024 [2] - The company held its annual shareholders' meeting on May 31, 2024, where the issuance of the short-term financing bonds was approved [2] - The company has previously issued several short-term financing bonds, with each issuance totaling RMB 5 billion, and all are yet to mature [3][4] Group 2 - The company successfully issued the seventh phase of its short-term financing bonds on August 7, 2025, raising RMB 5 billion, which was fully received by August 8, 2025 [6] - The funds raised from this issuance will be used to supplement working capital and repay bank loans [6]